Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
7.12
+0.08 (1.07%)
Apr 1, 2025, 3:45 PM EDT - Market open

Company Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States.

The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products.

The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022.

Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Lifecore Biomedical, Inc.
Lifecore Biomedical logo
Country United States
Founded 1986
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 524
CEO Paul Josephs

Contact Details

Address:
3515 Lyman Boulevard
Chaska, Minnesota 55318
United States
Phone (952) 368-4300
Website lifecore.com

Stock Details

Ticker Symbol LFCR
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year June - May
Reporting Currency USD
CIK Code 0001005286
ISIN Number US5147661046
Employer ID 94-3025618
SIC Code 2834

Key Executives

Name Position
Paul Josephs President, Chief Executive Officer and Director
James G. Hall Advisor
Ryan D. Lake CPA Executive Vice President, Chief Financial Officer and Secretary
Thomas Guldager Senior Vice President of Operations
Aaron Perlitsh Director of Internal Audit and Chief Compliance Officer
Darren M. Hieber Senior Vice President of Corporate Development and Partnerships
Jackie Q. Klecker Executive Vice President of Quality and Development Services
Dr. Albert D. Bolles Ph.D. President of Curation Foods, Inc.
Parker K. Javid Vice President

Latest SEC Filings

Date Type Title
Feb 27, 2025 DEF 14A Other definitive proxy statements
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 5, 2025 SCHEDULE 13G/A Filing
Jan 21, 2025 PRE 14A Other preliminary proxy statements
Jan 17, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 17, 2025 8-K Current Report
Jan 7, 2025 8-K Current Report
Jan 2, 2025 10-Q Quarterly Report
Jan 2, 2025 8-K Current Report